Viewing Study NCT05797493


Ignite Creation Date: 2025-12-25 @ 1:11 AM
Ignite Modification Date: 2025-12-25 @ 11:22 PM
Study NCT ID: NCT05797493
Status: RECRUITING
Last Update Posted: 2023-04-04
First Post: 2023-03-16
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Organization:

Study Overview

Official Title: Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
Status: RECRUITING
Status Verified Date: 2023-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PICASSO
Brief Summary: The scope of the PICASSO project is to apply an innovative patient-based pan-omic approach to immune-assays, that will include multi-omics tumour characterization (genome, proteome, transcriptome), blood immune-cells and cytokine profiling, serological screening for paraneoplastic autoantibodies, clinical and metabolic measurements.

The PICASSO project is aimed to validate in real world population the predictive role of SCLC transcriptomic classification (particularly, I-SCLC subtype) and to explore correlations with dynamic changes in peripheral blood immunity. Additionally, investigators expected to validate the predictive/prognostic role of emerging new variables, including metabolic-induced meta-inflammation alterations and subclinical auto-immunity.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: